FQFosca Quarti-Trevano

Fosca Quarti-Trevano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fosca Quarti-Trevano has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeting the Association between Interarm Blood Pressure Difference and Subclinical Organ Damage: Findings from the PAMELA Study

    by Cesare Cuspidi, Rita Facchetti, Fosca Quarti-Trevano, Marijana Tadic, Jennifer Vanoli, Giuseppe Mancia, Guido Grassi

    Background: Evidence on the association of interarm difference (IAD) in BP with subclinical cardiac and vascular damage in community-based populations is scanty. We addressed this issue in the participants to the Pressioni Monitorate E Loro Associazioni (PAMELA) study. Methods: The study included 527 participants who attended the third survey of the PAMELA study performed after 25 years from the initial evaluation. Data collection included medical history, anthropometric parameters, blood examinations, office BP, simultaneous IAD assessment, echocardiographic and cardio-ankle velocity index (CAVI) measurements. Results: In the whole study sample (age 66 ± 10 years, 49% males), the prevalence of systolic IAD (ie, IASD ≥ 10 mm Hg) was 12%. Although the association between IASD and left ventricular hypertrophy (LVH) (OR = 2.45, P = .007) disappeared after adjustment for several factors, this abnormal BP phenotype was twice as high in participants with LVH compared to those with normal LV geometry (21.7% vs 10.2%, P < .01). Furthermore, the prevalence of IASD in participants with LVH and LV remodeling was overall 3 times higher than in their normal counterparts. As for vascular damage, no relationship emerged between IASD with CAVI, treated either as a categorical (ie, CAVI > 9 m/second) or continuous variable. Conclusions: Our study provides a new piece of evidence on the value of IASD as a potential marker of LVH, which in turn reflects the burden of several coexisting cardiovascular risk factors. From a practical perspective, the detection of IASD could be a clinical rationale for investigating subclinical cardiac organ damage.


  • Open Access

    Sympathetic Overactivation in the Resistant Hypertensive Phenotype: A Meta-Analysis of Published Studies

    by Guido Grassi, Fosca Quarti-Trevano, Cesare Cuspidi, Elias Sanidas, Giuseppe Mancia, Costas Thomopoulos

    BACKGROUND: Indirect and direct approaches to assess sympathetic cardiovascular drive have shown that patients with essential hypertension responsive to the blood pressure–lowering effects of antihypertensive drugs are characterized by a pronounced adrenergic overactivity. Whether an emerging clinical hypertensive phenotype such as drug-resistant hypertension (RHT) is also characterized by sympathetic activation and whether its magnitude and underlying pathophysiological mechanisms differ from those of non-RHT is undefined. METHODS: Among the 54 studies identified providing information in RHT on muscle sympathetic nerve traffic (MSNA), 12 were eligible (508 patients) and meta-analyzed, grouping them based on clinically relevant questions: (1) Is MSNA increased in RHT? (2) Does the magnitude of the sympathetic activation differ from that observed in non-RHT? (3) Are heart rate and plasma norepinephrine valuable surrogate markers of MSNA in RHT? and (4) Is baroreflex-MSNA control impaired? RESULTS: MSNA was significantly greater in patients with RHT than in normotensive patients (73.2±6.6 versus 46.1±11.1 bursts/100 heartbeats, means±SD; P P <0.001), despite the greater number of antihypertensive drugs. At variance from non-RHT, in RHT, elevated MSNA was unrelated to heart rate and plasma venous norepinephrine. Similar to non-RHT, MSNA in RHT was inversely related to the baroreflex function. CONCLUSIONS: RHT is characterized by a sustained sympathetic overdrive, significantly greater in magnitude than the 1 detected in non-RHT. Neither heart rate nor norepinephrine are capable of reflecting the marked adrenergic overdrive seen in this condition via MSNA recordings.


  • Failure of Antihypertensive Treatment to Restore Normal Sympathetic Activity

    by Fosca Quarti-Trevano, Gino Seravalle, Rita Facchetti, Konstantinos Tsioufis, Kyriakos Dimitriadis, Eleni Manta, Giuseppe Mancia, Guido Grassi

    BACKGROUND: Sympathetic deactivation represents a major goal of antihypertensive drug treatment. However, whether treatment normalizes the hypertension-related sympathetic cardiovascular overdrive remains uncertain. METHODS: In 219 middle-aged essential hypertensives, we analyzed, along with office systolic and diastolic blood pressure (BP) and heart rate, muscle sympathetic nerve traffic (MSNA, microneurography) before and after 3-month treatment, either as monotherapy or as combination. Controls were represented by 100 age-matched normotensives. RESULTS: Treatment caused, along with a small heart rate decrease, a clear BP reduction (from 160.5/95.5 to 142.3/85.0 mm Hg, P P <0.01). A similar pattern was detected in patients under monotherapy (n=81) or combination drug treatment (n=138). MSNA was significantly related to systolic BP before and during treatment but unrelated to heart rate. In treated patients achieving the lower BP (135.1/84.5 mm Hg, n=90), the MSNA reduction was greater than that detected in patients with the higher on-treatment BP (146.7/87.4 mm Hg, n=129). However, even in patients achieving a BP target <140/90 mm Hg, MSNA remained markedly higher (on average +66.4%) compared with controls. This was the case even when treated BP was <130/80 mm Hg. Data were similar for different antihypertensive drug classes. CONCLUSIONS: Thus, antihypertensive treatment, even when effective in achieving BP control, fails to restore the level of normotension-related MSNA, with a persistence of the pattern of heightened sympathetic influences typical of untreated patients with hypertension. Failure of normalization may contribute to the development of the residual cardiovascular risk reported in treated hypertensives.


  • Renal Denervation

    by Fosca Quarti-Trevano, Guido Grassi

  • Open Access

    Association Between Arterial Stiffness, High Blood Pressure, and Hypertensive Phenotypes: Insights from the PAMELA Study

    by Fosca Quarti-Trevano, Cesare Cuspidi, Raffaella Dell’oro, Pasquale Ambrosino, Guido Grassi

    Hypertension is a clinical condition associated with structural alterations in small, medium, and large arteries, also affecting target organs due to the mechanical effects of high blood pressure and shear stress. However, these vascular changes are also influenced by various inflammatory and neurohumoral mediators originating from the endothelium, the renin-angiotensin-aldosterone system, the neuroadrenergic system, and the perivascular fat. Specifically, chronic hypertension leads to vascular stretching, which triggers complex signaling pathways that promote vascular remodeling. The endothelium plays a crucial role in this process, as its function is impaired in hypertensive patients, leading to reduced nitric oxide-mediated vasodilation, increased vascular tone, and a proinflammatory and prothrombotic state. Along with structural changes, hypertension also triggers dynamic alterations in arterial distensibility and arterial wall properties, leading to increased arterial stiffness, which is strongly linked to cardiovascular outcomes and associated disability, as well as subsequent rehabilitation needs. Several non-invasive and highly reproducible methods are currently used to assess arterial stiffness, one of which is the cardio-ankle vascular index (CAVI). This article examines the association between arterial stiffness and high blood pressure, with a particular focus on the results of the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. This study analyzes the determinants of arterial stiffness in the general population, the different hypertensive phenotypes affecting diurnal and nocturnal blood pressure profiles, and the impact of blood pressure control through antihypertensive treatment on arterial stiffness.


  • Reproducibility and Treatment Effect on Office and Ambulatory Pressure Relation

    by Giuseppe Mancia, Rita Facchetti, Fosca Quarti-Trevano, Guido Grassi

    BACKGROUND: In the absence of outcome-based ambulatory blood pressure (BP) trails hypertension guidelines provide 24-hour mean BP values corresponding to trial-validated office BP values. Data are shown for untreated and treated patients together, but whether corresponding ambulatory values are similar in untreated and treated hypertensives and reproducible at yearly measurements during treatment is undefined. METHODS: In 2397 patients of the ELSA (European Lacidipine Study on Atherosclerosis) and PHYLLIS (Plaque Hypertension Lipid-Lowering Italian Study) trials, we calculated the office and 24-hour BP relationship according to the linear regression model, with office systolic BP as the independent variable, at baseline and yearly during a 3-year treatment. Twenty-four hour BP values corresponding to clinically important office BP values (hypertension grading and treatment thresholds and targets) were calculated and compared with those provided by guidelines. RESULTS: Office and 24-hour systolic BP or diastolic BP always exhibited a significant linear relationship, with, however, limited Pearson correlation coefficients (never >0.44).The slopes of the relationship were superimposable between different years of treatment but always significantly less steep than the slope seen in untreated individuals. Compared with the guideline-provided corresponding values, 24-hour BP showed qualitative and quantitative differences; for example, it was considerably lower and higher than the guideline-corresponding values when office BP was in the high hypertension and low treatment target ranges, respectively. CONCLUSIONS: In treated patients with hypertension the slope of the office and 24-hour BP linear regression is reproducible over time. However, the slopes are steeper in untreated individuals, indicating that information on ambulatory BP values corresponding to office BP values can be more accurate if separately estimated in these 2 conditions.


  • Open Access

    Serum Uric Acid, Hypertriglyceridemia, and Carotid Plaques: A Sub-Analysis of the URic Acid Right for Heart Health (URRAH) Study

    by Claudia Agabiti Rosei, Anna Paini, Giacomo Buso, Alessandro Maloberti, Cristina Giannattasio, Massimo Salvetti, Edoardo Casiglia, Valerie Tikhonoff, Fabio Angeli, Carlo Maria Barbagallo, et al.

    High levels of serum uric acid (SUA) and triglycerides (TG) might promote high-cardiovascular-risk phenotypes, including subclinical atherosclerosis. An interaction between plaques xanthine oxidase (XO) expression, SUA, and HDL-C has been recently postulated. Subjects from the URic acid Right for heArt Health (URRAH) study with carotid ultrasound and without previous cardiovascular diseases (CVD) (n = 6209), followed over 20 years, were included in the analysis. Hypertriglyceridemia (hTG) was defined as TG ≥ 150 mg/dL. Higher levels of SUA (hSUA) were defined as ≥5.6 mg/dL in men and 5.1 mg/dL in women. A carotid plaque was identified in 1742 subjects (28%). SUA and TG predicted carotid plaque (HR 1.09 [1.04–1.27], p < 0.001 and HR 1.25 [1.09–1.45], p < 0.001) in the whole population, independently of age, sex, diabetes, systolic blood pressure, HDL and LDL cholesterol and treatment. Four different groups were identified (normal SUA and TG, hSUA and normal TG, normal SUA and hTG, hSUA and hTG). The prevalence of plaque was progressively greater in subjects with normal SUA and TG (23%), hSUA and normal TG (31%), normal SUA and hTG (34%), and hSUA and hTG (38%) (Chi-square, 0.0001). Logistic regression analysis showed that hSUA and normal TG [HR 1.159 (1.002 to 1.341); p = 0.001], normal SUA and hTG [HR 1.305 (1.057 to 1.611); p = 0.001], and the combination of hUA and hTG [HR 1.539 (1.274 to 1.859); p = 0.001] were associated with a higher risk of plaque. Our findings demonstrate that SUA is independently associated with the presence of carotid plaque and suggest that the combination of hyperuricemia and hypertriglyceridemia is a stronger determinant of carotid plaque than hSUA or hTG taken as single risk factors. The association between SUA and CVD events may be explained in part by a direct association of UA with carotid plaques.


  • Mechanisms of Vascular Inflammation and Potential Therapeutic Targets: A Position Paper From the ESH Working Group on Small Arteries

    by Francisco J Rios, Carolina de Ciuceis, Georgios Georgiopoulos, Antonios Lazaridis, Ryszard Nosalski, George Pavlidis, Simon Tual-Chalot, Claudia Agabiti-Rosei, Livia L Camargo, Edyta Dąbrowska, et al.

    Inflammatory responses in small vessels play an important role in the development of cardiovascular diseases, including hypertension, stroke, and small vessel disease. This involves various complex molecular processes including oxidative stress, inflammasome activation, immune-mediated responses, and protein misfolding, which together contribute to microvascular damage. In addition, epigenetic factors, including DNA methylation, histone modifications, and microRNAs influence vascular inflammation and injury. These phenomena may be acquired during the aging process or due to environmental factors. Activation of proinflammatory signaling pathways and molecular events induce low-grade and chronic inflammation with consequent cardiovascular damage. Identifying mechanism-specific targets might provide opportunities in the development of novel therapeutic approaches. Monoclonal antibodies targeting inflammatory cytokines and epigenetic drugs, show promise in reducing microvascular inflammation and associated cardiovascular diseases. In this article, we provide a comprehensive discussion of the complex mechanisms underlying microvascular inflammation and offer insights into innovative therapeutic strategies that may ameliorate vascular injury in cardiovascular disease.


  • Habitual Regular Coffee Consumption and Arterial Stiffness: Data From the 3rd Pamela Survey

    by Raffaella Dell’oRo, Fosca Quarti-Trevano, Rita Facchetti, Cesare Cuspidi, Giuseppe Mancia, Guido Grassi

    We evaluated whether chronic coffee consumption affects arterial stiffness, assessed by cardio-ankle vascular index (CAVI). In 514 subjects, aged 66.6±9.9 yrs (mean±SD), recruited in the 3rd follow-up of the PAMELA study, subdivided in 3 groups according to daily intake of regular coffee (0, 1-2 and ≥3 cups/day), we measured CAVI and clinic, ambulatory blood pressure (BP) and other variables. The 3 groups displayed similar age, gender, metabolic and renal pofile. Clinic and ambulatory BPs were similar in the 3 groups, this being the case for CAVI (0 cup: 9.1±1.8, 1-2 cups: 9.5±2.3 and ≥3 cups: 9.2±2.1 m/sec, P=NS). No significant gender-difference in CAVI and in participants under antihypertensive treatment was detected. our data show that chronic coffee consumption leaves unaffected arterial stiffness in the general population, this being the case in subgroups. The neutral vascular impact of coffee may favor the absence of any significant BP effect of habitual coffee intake.


  • Open Access

    Triglyceride-glucose Index and Mortality in a Large Regional-based Italian Database (URRAH Project)

    by Lanfranco D’elia, Maria Masulli, Agostino Virdis, Edoardo Casiglia, Valerie Tikhonoff, Fabio Angeli, Carlo Maria Barbagallo, Michele Bombelli, Federica Cappelli, Rosario Cianci, et al.

    Purpose: Recently, a novel index [the triglyceride-glucose (TyG) index]) was considered a surrogate marker of insulin resistance (IR); in addition, it was estimated to be a better expression of IR than widely used tools. Few and heterogeneous data are available on the relationship between this index and mortality risk in non-Asian populations. Therefore, we estimated the predictive role of baseline TyG on the incidence of all-cause and cardiovascular (CV) mortality in a large sample of the general population. Moreover, in consideration of the well-recognized role of serum uric acid (SUA) on CV risk and the close correlation between SUA and IR, we also evaluated the combined effect of TyG and SUA on mortality risk. Methods: The analysis included 16 649 participants from the URRAH cohort. The risk of all-cause and CV mortality was evaluated by the Kaplan–Meier estimator and Cox multivariate analysis. Results: During a median follow-up of 144 months, 2569 deaths occurred. We stratified the sample by the optimal cut-off point for all-cause (4.62) and CV mortality (4.53). In the multivariate Cox regression analyses, participants with TyG above cut-off had a significantly higher risk of all-cause and CV mortality than those with TyG below the cut-off. Moreover, the simultaneous presence of high levels of TyG and SUA was associated with a higher mortality risk than none or only 1 of the 2 factors. Conclusion: The results of this study indicate that these TyG (a low-cost and simple, noninvasive marker) thresholds are predictive of an increased risk of mortality in a large and homogeneous general population. In addition, these results show a synergic effect of TyG and SUA on the risk of mortality.